Sandipkumar S. Kapadia
Directeur Financier/CFO chez HARMONY BIOSCIENCES HOLDINGS, INC.
Fortune : - $ au 30/06/2024
Profil
Sandipkumar S.
Kapadia is currently an Independent Director at Molecular Partners AG, an Independent Non-Executive Director at Passage Bio, Inc., a Director at Intercept Pharma Europe Ltd., a Director at Molecular Partners, Inc., a Director at VectivBio AG, a Director at Alentis Therapeutics AG, and the Chief Financial & Administrative Officer at Harmony Biosciences Holdings, Inc. He previously served as a Director at Intercept Pharma UK & Ireland Ltd., a Co-Managing Director at Intercept Pharma Deutschland GmbH, a Director at Therachon AG, an Independent Director at VectivBio Holding AG, the Chief Financial Officer & Vice President at Sandoz, Inc., the Chief Financial Officer & Treasurer at Intercept Pharmaceuticals, Inc., the Chief Financial Officer & Vice President at Novartis Pharmaceuticals UK Ltd., and the Head-Finance at Novartis Pharmaceuticals Corp.
and Novartis Pharmaceuticals AG.
He also held the position of Chief Financial Officer & Vice President at Novartis Pharmaceuticals BV and was a Member-Supervisory Board at Therachon Holding GmbH.
Mr. Kapadia holds an MBA from Rutgers State University of New Jersey and an undergraduate degree from Montclair State University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/04/2024 | 0 ( -.--% ) | - $ | 30/06/2024 | |
PASSAGE BIO, INC.
-.--% | 21/05/2024 | 0 ( -.--% ) | - $ | 30/06/2024 |
Postes actifs de Sandipkumar S. Kapadia
| Sociétés | Poste | Début |
|---|---|---|
| PASSAGE BIO, INC. | Directeur/Membre du Conseil | 01/12/2019 |
| MOLECULAR PARTNERS AG | Directeur/Membre du Conseil | 01/04/2020 |
| HARMONY BIOSCIENCES HOLDINGS, INC. | Directeur Financier/CFO | 29/03/2021 |
Molecular Partners, Inc.
 Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | Directeur/Membre du Conseil | - |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Directeur/Membre du Conseil | 15/12/2020 |
Intercept Pharma Europe Ltd.
 Intercept Pharma Europe Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2014, Intercept Pharma Europe Ltd. is a subsidiary of Intercept Pharmaceuticals, Inc. that researches, develops, and sells pharmaceutical products. The company is based in Bristol, UK. | Directeur/Membre du Conseil | 28/09/2016 |
Alentis Therapeutics AG
 Alentis Therapeutics AG Pharmaceuticals: MajorHealth Technology Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland. | Directeur/Membre du Conseil | - |
Anciens postes connus de Sandipkumar S. Kapadia
| Sociétés | Poste | Fin |
|---|---|---|
| VECTIVBIO HOLDING AG | Directeur/Membre du Conseil | 26/06/2023 |
| INTERCEPT PHARMACEUTICALS, INC. | Directeur Financier/CFO | 26/03/2021 |
| ░░░░░░░░░ ░░░░░░ ░░ ░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Sandipkumar S. Kapadia
| Rutgers State University of New Jersey | Masters Business Admin |
| Montclair State University | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
| MOLECULAR PARTNERS AG | Health Technology |
| HARMONY BIOSCIENCES HOLDINGS, INC. | Health Technology |
| PASSAGE BIO, INC. | Health Technology |
| Entreprise privées | 14 |
|---|---|
Sandoz, Inc.
 Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ. | Health Technology |
Novartis Pharmaceuticals UK Ltd.
 Novartis Pharmaceuticals UK Ltd. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals UK Ltd. manufactures medicines and drugs. The company is headquartered in Camberley, the United kingdom. | Health Technology |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
| Novartis Pharmaceuticals AG | |
Novartis Pharmaceuticals BV
 Novartis Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals BV is a Dutch company that manufactures pharmaceutical products. The private company is based in Arnhem, Netherlands. | Health Technology |
Therachon Holding GmbH
 Therachon Holding GmbH BiotechnologyHealth Technology Therachon Holding GmbH engages in the acquisition, management, financing, and disposal of participating interests in firms. It also acquires, holds, and disposes intellectual property rights. The company was founded on December 22, 2015 and is headquartered in Basel, Switzerland. | Health Technology |
Alentis Therapeutics AG
Alentis Therapeutics AG Pharmaceuticals: MajorHealth Technology Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland. | Health Technology |
Intercept Pharma Europe Ltd.
Intercept Pharma Europe Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 2014, Intercept Pharma Europe Ltd. is a subsidiary of Intercept Pharmaceuticals, Inc. that researches, develops, and sells pharmaceutical products. The company is based in Bristol, UK. | Commercial Services |
Intercept Pharma UK & Ireland Ltd.
 Intercept Pharma UK & Ireland Ltd. Medical DistributorsDistribution Services Founded in 2015, Intercept Pharma UK & Ireland Ltd. is a pharmaceutical wholesaler. Part of Intercept Pharmaceuticals, Inc., the company is based in Bristol, UK. | Distribution Services |
Intercept Pharma Deutschland GmbH
 Intercept Pharma Deutschland GmbH Medical DistributorsDistribution Services Part of Intercept Pharmaceuticals, Inc., Intercept Pharma Deutschland GmbH is a German company focused on building a healthier tomorrow for patients with progressive non-viral liver diseases. The company is based in Munich, Germany. The CEOs are Rocco Venezia, Michael Gemellaro, Willem Wouter Van Weperen. The company was founded in 2015. | Distribution Services |
Molecular Partners, Inc.
Molecular Partners, Inc. Pharmaceuticals: MajorHealth Technology Part of Molecular Partners AG, Molecular Partners, Inc. operates as a clinical-stage biopharmaceutical company. The company is based in Cambridge, MA. The CEO of the company is Patrick Amstutz. | Health Technology |
| Therachon AG | |
VectivBio Holding AG
 VectivBio Holding AG Pharmaceuticals: MajorHealth Technology VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of treatments for severe rare conditions with significant unmet medical need. It operates through Switzerland, Canada, and the United States geographical segment. The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland. | Health Technology |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Health Technology |
